Welcome to our dedicated page for LMDX news (Ticker: LMDX), a resource for investors and traders seeking the latest updates and insights on LMDX stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect LMDX's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of LMDX's position in the market.
LumiraDx (Nasdaq: LMDX) has expanded the intended use of its FDA Emergency Use Authorization (EUA) SARS-CoV-2 Antigen Test to include asymptomatic individuals. Previously, the test was authorized for symptomatic patients. With performance data revealing an 82.1% positive agreement and 100% negative agreement with RT-PCR in asymptomatic subjects, this expansion aims to support widespread screening to help control COVID-19 transmission. The test, which has been utilized by various healthcare institutions globally, demonstrates high sensitivity compared to other antigen tests.
LumiraDx (Nasdaq: LMDX) has received emergency use approval from India's Central Drugs Standard Control Organisation for its SARS-CoV-2 Antigen test. This test offers results in under 12 minutes with high accuracy, demonstrating 97.6% positive and 96.6% negative agreements with PCR tests in clinical studies. The company aims to enhance point-of-care diagnostics in India, which currently faces significant healthcare needs. LumiraDx's platform is already in use in various markets, including the UK and US, and the company is expanding its test offerings globally.
LumiraDx (Nasdaq: LMDX) announced on October 15, 2021, the submission of its LumiraDx SARS-CoV-2 & Flu A/B Test to the FDA for Emergency Use Authorization. This test is designed to simultaneously detect SARS-CoV-2, Influenza A, and Influenza B, expediting diagnosis for patients within 12 days of symptom onset. The test is part of a broader platform offering multiple assays, with five currently on the market and ten more planned for regulatory submission by 2022. The initiative is supported by funding from the NIH RADx program.
LumiraDx, a next-generation point of care diagnostic testing company, has completed its merger with CA Healthcare Acquisition Corp. (CAHC), valuing LumiraDx at $3.0 billion. The merger was approved by CAHC stockholders, and LumiraDx's common shares will start trading on September 29, 2021 under the ticker symbol LMDX. LumiraDx aims to transform diagnostic testing with over 30 assays targeting infectious diseases, cardiovascular diseases, and more, with existing contracts across multiple global health organizations.